A nationally representative U.S. panel study of over 33,000 adults finds that people who use cannabis under a medical recommendation consume it significantly more often than recreational-only users at every age from 19 to 65. The apparent increase in medical use among older cannabis users reflects declining recreational-only use with age, not a true rise in medical uptake, underscoring that medical status consistently identifies a higher-frequency use subgroup rather than a growing population trend.

Medical cannabis programs are expanding rapidly in the United States, yet clinicians and policymakers have lacked nationally representative data on who actually uses cannabis under a medical recommendation and how their consumption patterns compare with recreational-only users. Understanding whether medical status marks a distinct use profile is essential for designing screening protocols, anticipating drug interactions, and counseling patients about frequency-related risks. Without this epidemiological baseline, clinical conversations about cannabis use remain untethered from population-level evidence.

This study draws on the Monitoring the Future (MTF) Panel Study, which follows nationally representative cohorts of U.S. 12th graders into adulthood with repeated surveys through age 65. Beginning in 2018, the MTF added questions about whether cannabis use was based on the respondent’s own written medical recommendation or prescription. The investigators analyzed 40,926 observations from 33,647 respondents collected between 2018 and 2023 to characterize the prevalence, developmental trajectory, and temporal trends of medical cannabis use across three adult age groups (19 to 30, 35 to 45, and 50 to 65), and to compare use frequency between medical and recreational-only users. Multinomial, logistic, and negative binomial regression models with panel survey weights were used to test associations.

Medical cannabis use was rare in the overall sample (2.6% of all observations) but accounted for nearly 10% of past-year cannabis users. Among users, the proportion reporting medical use increased significantly with age, but this pattern was driven entirely by a parallel decline in recreational-only use rather than any absolute increase in medical cannabis uptake across the full population. Medical users reported significantly higher past 30-day cannabis prevalence and frequency than recreational-only users across all age groups (p<0.001). Medical-use prevalence grew over time only in states with medical-only legalization, not in states with recreational legalization. Male gender was the sole sociodemographic factor consistently associated with medical use after multiple-testing correction. The study’s reliance on self-report and a 39% panel response rate are notable limitations, and the observational design precludes any causal inference about whether medical status drives heavier use or heavier users seek medical recommendations. The authors emphasize that longitudinal research with clinical outcome data is needed to clarify these relationships.

This study does something genuinely useful: it quantifies what many of us in clinical practice already sense, that patients with medical cannabis recommendations tend to use cannabis more frequently and more consistently than recreational-only users. The MTF dataset is well-established and the analytic approach is rigorous. But the headline finding conceals a critical ambiguity the study cannot resolve. We do not know whether having a medical recommendation encourages more frequent use, or whether people who already use cannabis heavily are simply more motivated to obtain a recommendation. That distinction matters enormously for how we counsel patients.

In my practice, I treat the frequency question as a clinical conversation starter, not a judgment. When a patient tells me they use cannabis daily under a medical recommendation, I want to understand the indication, the dose, the formulation, and whether they feel the regimen is actually working. I find that frequent medical users often have chronic conditions that genuinely benefit from consistent cannabinoid exposure, but they also deserve the same pharmacovigilance we would apply to any daily medication. This study gives me better population-level context for that conversation, even if it cannot tell me which individual patients are using too much or too little.

This study sits in an important early position in the research arc for medical cannabis epidemiology. Prior work has documented rising cannabis use among older adults and the expansion of state medical programs, but few investigations have used nationally representative longitudinal data to compare medical and recreational-only use profiles across the full adult lifespan. The finding that medical use prevalence grew over time only in medical-only legalization states is particularly notable, suggesting that recreational legalization may absorb some individuals who would otherwise seek medical access, which has implications for projecting patient volumes and regulatory demand in evolving policy landscapes.

From a pharmacological standpoint, the consistent finding that medical users report higher daily or near-daily use underscores the importance of monitoring for tolerance development, cannabinoid-drug interactions, and potential withdrawal symptoms in this subgroup. Clinicians prescribing medications metabolized by CYP3A4 or CYP2C9 should be especially attentive when patients disclose daily medical cannabis use. The practical recommendation from this evidence is straightforward: when a patient reports a medical cannabis recommendation, treat that disclosure as a prompt for a thorough frequency and formulation assessment rather than assuming it implies moderate or controlled use.

Have thoughts on this? Share it: